Hemophilia Therapeutics Pipeline to Witness Major Collaborations in The Future: P&S Market Research

NEW YORK, Aug. 25, 2017 -- According to a new research report “Hemophilia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Hemophilia currently exhibits a strong pipeline with 53 drug candidates.

Hemophilia is a genetic disorder characterized by excessive bleeding and delayed blood clotting. There are two types of hemophilia, hemophilia A (also known as classic hemophilia) and hemophilia B. According to the Centers for Disease Control and Prevention, the incidence of hemophilia stands at, one out of every 5,000 male births and as many as 20,000 males in the U.S., living with either of the two types of hemophilia, presently. The prevalence of hemophilia A is around four times high as compared to the prevalence of hemophilia B. It has been observed that the male population is more commonly affected by the disease, as compared to the female population, since hemophilia is inherited in an X-linked recessive genetic pattern, where females are generally carriers of the disease. Hemophilia A results from a deficiency of clotting Factor VIII, whereas hemophilia B (also known as the Christmas disease) is caused by a deficiency of clotting Factor IX, both of these are essential for the proper functioning of blood clotting. The cause of the deficiency of clotting factors is thought to be a mutation in one of the genes that codes for the synthesis of these clotting factor, which are required to form a blood clot.

Request for sample of this research report: https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis/report-sample

Significant growth is expected in the therapeutic pipeline of hemophilia, mainly attributed to increasing collaboration between pharma as well as biotech companies, educational institutes and associations for the development of hemophilia therapeutics. Increasing prevalence of hemophilia and technological advancement are some of the major factors for the development of novel therapies for treatment of hemophilia. Positive clinical results of Phase III and Phase II drug candidates with lesser side effects are supporting the development of hemophilia therapeutics. Many awareness programs organized by pharma as well as biotechnology companies are supporting the development of hemophilia therapeutics pipeline. PolyXen is an enabling platform technology for protein drug delivery. Zinc finger nuclease mediated in vivo genome editing approach makes use of the endogenous albumin gene locus, a highly expressing and liver-specific site that can be edited with ZFNs to accept and express therapeutic genes. As of June 2017, the hemophilia pipeline comprises of approximately 53 drug candidates in the pipeline for the treatment of hemophilia in different stages of development.

Make Enquiry to Purchase this Research: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hemophilia-therapeutics-pipeline-analysis

Some of the other key players developing drugs for the treatment of hemophilia include, Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH and others.

More Reports By P&S Market Research

Synovial Sarcoma Therapeutics Pipeline Analysis, 2017

Synovial sarcoma is rare type of cancer and approximately one to three people in every million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect people at any age. Synovial sarcoma is more common in males, and the ratio of the disease stands at 12 males for every ten females. Synovial sarcoma often begins in the legs or arms; however, it can affect any area of the body.

https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis

Uveitis Therapeutics Pipeline Analysis, 2017

Uveitis includes symptoms such as blurred vision, dark, floating spots in the vision, redness in the eye, pain and sensitivity to light. The disease is diagnosed by examining the symptoms and eye examination, which includes an eye chart or visual acuity test, a funduscopic exam, ocular pressure and a slit lamp exam. Uveitis is treated by first eliminating inflammation, alleviating pain, preventing further tissue damage and restoring any loss of vision.

https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis

Amyotrophic Lateral Sclerosis Pipeline Analysis, 2017

Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region.

https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis

About P&S Market Research

P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.

With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication.  Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.

Contact:
Abhishek
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: [email protected]
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook